Modulation of the Effect of 1-beta-D-arabinofuranosylcytosine Based on Changes of Cytidine Deaminase Activity in HL60 Cells

Overview

Journal Med Oncol Tumor Pharmacother

Specialties Oncology
Pharmacology

Date 1990 Jan 1

PMID 2338846

Authors

J N Mejer

B T Mortensen

I J Christensen

Affiliations

Soon will be listed here.

Abstract

The effect of changes in cytidine deaminase activity on the growth inhibitory effect of 1-beta-D-arabinofuranosylcytosine (Ara-C) has been investigated in the human promyelocytic cell line, HL60. 1,25 Dihydroxy vitamin D3 (vit. D3), which is an inducer of differentiation, caused an increase of cytidine deaminase in HL60 cells simultaneous with an inhibition of the effect of Ara-C. On the other hand, retinoic acid, which also induces differentiation had no influence on either the activity of cytidine deaminase or the effect of Ara-C. An atoxic inhibitor of cytidine deaminase tetrahydrouridine, THU, enhanced the effect of Ara-C. THU also enhanced the effect of Ara-C, even if the Ara-C effect was inhibited by deoxycytidine. These results show that it is possible to modulate the effect of Ara-C by changing the activity of cytidine deaminase. Furthermore, changes in the activity of cytidine deaminase and the effect on the Ara-C growth inhibition vary dependent on the differentiating inducer used.

References

CAMIENER G, Smith C . Studies of the enzymatic deamination of cytosine arabinoside. I. Enzyme distribution and species specificity. Biochem Pharmacol. 1965; 14(10):1405-16. DOI: 10.1016/0006-2952(65)90175-9. View

Grant S, Bhalla K, Gleyzer M . Interaction of deoxycytidine and deoxycytidine analogs in normal and leukemic human myeloid progenitor cells. Leuk Res. 1986; 10(9):1139-46. DOI: 10.1016/0145-2126(86)90059-7. View

Chabner B, Johns D, Coleman C, Drake J, Evans W . Purification and properties of cytidine deaminase from normal and leukemic granulocytes. J Clin Invest. 1974; 53(3):922-31. PMC: 333075. DOI: 10.1172/JCI107633. View

Bhalla K, MacLaughlin W, Cole J, Arlin Z, Baker M, Graham G . Deoxycytidine preferentially protects normal versus leukemic myeloid progenitor cells from cytosine arabinoside-mediated cytotoxicity. Blood. 1987; 70(2):568-71. View

Smets L . S1-phase cells of the leukemic cell cycle sensitive to 1-beta-D-arabinofuranosylcytosine at a high-dose level. Cancer Res. 1985; 45(7):3113-7. View

Coleman C, Stoller R, Drake J, Chabner B . Deoxycytidine kinase: properties of the enzyme from human leukemic granulocytes. Blood. 1975; 46(5):791-803. View

Mejer J, Mortensen B . Changes in the activities of cytidine deaminase during differentiation of HL60 cells induced by 1,25 dihydroxy D3. Leuk Res. 1988; 12(5):405-9. DOI: 10.1016/0145-2126(88)90059-8. View

Harris A, Grahame-Smith D . Cytosine arabinoside triphosphate production in human leukaemic myeloblasts: interactions with deoxycytidine. Cancer Chemother Pharmacol. 1981; 5(3):185-92. DOI: 10.1007/BF00258478. View

Ishikura H, Okazaki T, Mochizuki T, Izumi Y, Tashima M, Sawada H . Effect of antimetabolites and thymidine blockage on the induction of differentiation of HL-60 cells by retinoic acid or 1 alpha,25-dihydroxyvitamin D3. Exp Hematol. 1985; 13(10):981-8. View

10.

Momparler R, Fischer G . Mammalian deoxynucleoside kinase. I. Deoxycytidine kinase: purification, properties, and kinetic studies with cytosine arabinoside. J Biol Chem. 1968; 243(16):4298-304. View

11.

Grant S, Bhalla K, Rauscher 3rd F, Cadman E . Potentiation of 1-beta-D-arabinofuranosylcytosine metabolism and cytotoxicity by 2,3-dihydro-1H-imidazolo[1,2-b]pyrazole in the human promyelocytic leukemic cell, HL-60. Cancer Res. 1983; 43(11):5093-100. View

12.

Mekras J, Boothman D, GREER S . Use of 5-trifluoromethyldeoxycytidine and tetrahydrouridine to circumvent catabolism and exploit high levels of cytidine deaminase in tumors to achieve DNA- and target-directed therapies. Cancer Res. 1985; 45(11 Pt 1):5270-80. View

13.

Fridland A, Verhoef V . Mechanism for ara-CTP catabolism in human leukemic cells and effect of deaminase inhibitors on this process. Semin Oncol. 1987; 14(2 Suppl 1):262-8. View

14.

Ho D, Carter C, Brown N, Hester J, McCredie K, Benjamin R . Effects of tetrahydrouridine on the uptake and metabolism of 1-beta-D-arabinofuranosylcytosine in human normal and leukemic cells. Cancer Res. 1980; 40(7):2444-6. View

15.

Collins S, Gallo R, Gallagher R . Continuous growth and differentiation of human myeloid leukaemic cells in suspension culture. Nature. 1977; 270(5635):347-9. DOI: 10.1038/270347a0. View

16.

CAMIENER G . Studies of the enzymatic deamination of ara-cytidine. V. inhibition in vitro and in vivo by tetrahydrouridine and other reduced pyrimidine nucleosides. Biochem Pharmacol. 1968; 17(9):1981-91. DOI: 10.1016/0006-2952(68)90114-7. View

17.

Kreis W, Chan K, Budman D, SCHULMAN P, Allen S, Weiselberg L . Effect of tetrahydrouridine on the clinical pharmacology of 1-beta-D-arabinofuranosylcytosine when both drugs are coinfused over three hours. Cancer Res. 1988; 48(5):1337-42. View